Revista nº 812

133 Actual Med. 2021; 106(812): 121- 133 Rivera Izquierdo M, et al. | Factores asociados a la mortalidad en residencias por Covid-19 13. Rong-Hui D, Li-Rong L, Cheng-Qing Y, et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur Respir J. 2020. https://doi.org/10.1183/13993003.00524-2020 14. Abbatecola AM, Antonelli-Incalz R. COVID-19 Spiraling of Frailty in Older Italian Patients. J Nutr Health Aging. 2020;24:453-5. https://doi.org/10.1007/s12603-020- 1357-9 15. Severe Outcomes Among Patients with Coronavirus Disea- se 2019 (COVID-19)-United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343-6. https://doi.org/10.15585/mmwr.mm6912e2 16. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to CO- VID-19 in Italy. JAMA. 2020. https://doi.org/10.1001/ jama.2020.4683 17. Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020; S0163-4453(20)30146-8. https://doi.org/10.1016/j. jinf.2020.03.019 18. Organización Mundial de la Salud. Informe the la Misión en China sobre la Enfermedad por Coronavirus 2019 (CO- VID-19). Disponible en: https://www.who.int/docs/de- fault-source/coronaviruse/who-china-joint-mission-on- covid-19-final-report.pdf 19. Centro Nacional de Epidemiología. Red Nacional de Vigi- lancia Epidemiológica. Informe sobre la situación de CO- VID-19 en España. Informe 14, 2020. Disponible en: https:// www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPu- blicaRENAVE/EnfermedadesTransmisibles/Documents/ INFORMES/Informes%20COVID19/Informe%20n%C2%- BA%2014.%20Situaci%C3%B3n%20de%20COVID19%20 en%20Espa%C3%B1a%20a%2024%20marzo%20de%20 2020.pdf 20. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [published correction appears in JAMA. 2020 May 26;323(20):2098]. JAMA. 2020;323(20):2052-9. https://doi.org/10.1001/jama.2020.6775 21. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correc- tion appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-62. https://doi.org/10.1016/S0140-6736( 20)30566-3 22. Feng K, Chen Z, Mei B, Du X, Fu X. Quickly SOFA Sco- re Can Be Used as a High-Efficiency Classified Method for COVID-19 Infected Patients. Iran J Public Heal- th. 2020;49(8):1594-6. https://doi.org/10.18502/ijph. v49i8.3915 23. Rivera-Izquierdo M, Valero-Ubierna MDC, Martínez-Diz S, et al. Clinical Factors, Preventive Behaviours and Temporal Outcomes Associated with COVID-19 Infection in Heal- th Professionals at a Spanish Hospital. Int J Environ Res Public Health. 2020;17(12):4305.  https://doi.org/10.3390/ ijerph17124305. 24. Rivera-Izquierdo M, Valero-Ubierna MDC, R-delAmo JL, et al. Therapeutic agents tested in 238 COVID-19 hospitali- zed patients and their relationship with mortality. Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad. Med Clin (Barc). 2020;155(9):375-81. https://doi.org/10.1016/j.me- dcli.2020.06.025 25. Romero-Duarte Á, Rivera-Izquierdo M, Guerrero-Fernán- dez de Alba I, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the AN- COHVID multicentre 6-month follow-up study. BMC Med. 2021;19(1):129. https://doi.org/10.1186/s12916-021- 02003-7 Los autores/as de este artículo declaran no tener nin- gún tipo de conflicto de intereses respecto a lo ex- puesto en el presente trabajo. CONFLICTO DE INTERESES Si desea citar nuestro artículo: Rivera Izquierdo M, Romero Duarte Á, Cárdenas Cruz A. Factores asociados a la mortalidad y secuelas en usuarios de residencias para personas mayores hospitalizados por COVID-19: un estudio longitudinal con 6 meses de seguimiento. Actual Med. 2021; 106(812): 121- 133. DOI: 10.15568/ am.2021.812.prm01